DC371739

• Description :

  DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia[1][2].

• CAS Number :

  [2135765-21-6]

• UNSPSC :

  12352005

• Target :

  ANGPTL; PCSK9

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/dc371739.html

• Purity :

  95.56

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  OCN1C2=C(C3=C1CN4CCC5=CC(OCC6=CC=CC=C6)=C(C=C5C4C3)OC)C=C(OC)C=C2

• Molecular Formula :

  C29H30N2O4

• Molecular Weight :

  470.56

• References & Citations :

  [1]Bao X, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) : from bench to bedside. Signal Transduct Target Ther. 2024 Jan 8;9 (1) :13.|[2]Wang J, et al. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial. Cell Metab. 2022 May 3;34 (5) :667-680.e6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1